An Open-Label, Extension Safety Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With HIV Neuropathy - Not applicable

Pfizer Limited0 个研究点目标入组 400 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Subjects who participated in the preceding A0081244 double-blind trial and completed at least through Visit 9 of that trial.
•2. Subjects with painful distal sensory polyneuropathy (DSP) interested in treatment based on investigator clinical judgment.
•3. Subjects who had acceptable tolerability of study drug in A0081244.
•Note: There is no upper age limit criteria per the protocol

•1.Clinically significant or unstable conditions that, in the opinion of the investigator, would compromise participation in the study. This includes, for example, medical conditions such as, but not limited to: hepatic, renal, respiratory, hematological, immunological, cardiovascular diseases, arrhythmia, inflammatory or rheumatologic disease, active infections, symptomatic peripheral vascular disease, psychiatric illness, and untreated endocrine disorders.
•2.Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
•3.Active Acquired Immune Deficiency Syndrome (AIDS)- defining Opportunistic Infection (OI) that requires hospitalization.

发起方